Although current studies have made great efforts to clarify the epigenetic landscape alterations modified by mutated DNMT3A [24, 25], the advances are far from satisfactory in unraveling the association between DNMT3A mutation and the inferior clinical outcomes in AML patients, which limited the development of novel targeted therapy against the mutation. Here, DNMT3A is linked to acute myeloid leukemia.